Lamotrigine and the risk of fulminant hepatic failure

Lancet

Volumn 370, Issue 9605, 2007, Pages 2101-

  Iniesta, Ivan ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

AUTOPSY; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG EXPOSURE; HOSPITALIZATION; HUMAN; LETTER; LIVER FAILURE; MONONUCLEOSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 37349040175     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61900-X     Document Type: Letter

References (2)

1. Shawcross D., Knighton S., Bernal W., Sizer E., and Auzinger G. Old versus new antiepileptic drugs: the SANAD study. Lancet 370 (2007) 314-315
2. Marson A., Al-Kharusi A., Alwaidh M., et al., on behalf of the SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015